Your session is about to expire
← Back to Search
AZD5363 for Prostate Cancer
Study Summary
This trial will study the recommended dose of AZD5363 in patients with specific AKT mutations, in combination with standard breast cancer (fulvestrant) or prostate cancer (enzalutamide) drugs.
- Solid Tumors
- Prostate Cancer
- Breast Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 1 trial • 33 Patients • NCT01895946Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What medical conditions is AZD5363 typically employed to alleviate?
"AZD5363 is the recommended treatment for pik3ca gene mutation, but has also been used in cases of malignant neoplasms, disease progression and castration."
Is this experimental treatment still taking on new participants?
"This trial is no longer recruiting, having been initially posted on October 11th 2017 and last edited on July 5th 2022. On the other hand, 5046 clinical trials for breast cancer are currently seeking patients as well as 244 studies concerning AZD5363."
How trustworthy is AZD5363 to ensure patient safety?
"Because this is a Phase 1 trial, meaning that there has been limited safety and efficacy data collected thus far, our team at Power rated AZD5363 as a '1' in terms of its perceived safety."
How many participants are enrolled in this research endeavor?
"This research endeavour is no longer accepting applications. First posted on October 11th 2017, the project was last edited on July 5th 2022. Those seeking similar trials can find 5046 studies related to breast cancer and 244 involving AZD5363 actively enrolling patients at this time."
Are there any other research endeavors that have utilized AZD5363?
"Currently, 244 studies analyzing AZD5363 are underway. Of these active trials, 64 have entered Phase 3. Shanghai is the primary location for this research; however, 15339 medical sites globally are trialing it as well."
Share this study with friends
Copy Link
Messenger